About MC3

Founded in 1991 with the specific aim of commercializing intellectual property related to artificial heart and lung technologies from the University of Michigan, MC3 has grown to become one of the most respected names in the cardiopulmonary research community.

From its initial goal of advancing early-stage medical devices extracorporeal support technologies, MC3 has emerged as a leader in creating forward-thinking solutions to the world’s most challenging disease etiologies.

The Company continues to grow organically and, in 2013, MC3 secured an additional capital infusion specifically to explore complementary acquisition candidates and expand manufacturing capabilities.

MC3’s DNA remains grounded in scientific discovery with an invigorated focus on commercializing innovative products and therapy strategies enabling it to better respond to today’s unmet clinical needs.

heart lung rendering


Management Team

Scott Merz
President & CEO, Co-Founder

Catherine Schmidt
Chief Financial Officer

Bill Sidor
Vice President Engineering

Kathy Osterholzer
Research Manager

Martha Rumford
Regulatory Affairs & Quality Compliance Manager

Ted Chittenden
Vice President Operations & Manufacturing

Rio Foster
Vice President Sales & Marketing

Board of Directors

Robert Foster
Chairman of the Board

Bob Bartlett M.D.
Co-Founder, Professor Emeritus University of Michigan

Scott Merz
President & CEO, Co-Founder

Chris Ball
Director, Brockett Tamny & Co.

Bill Sidor
Vice President Engineering

Rio Foster
Vice President Sales & Marketing



MC3 Cardiopulmonary, Inc.
2555 Bishop Circle W.
Dexter, MI 48130

phone: +1 734.995.9089
e-mail: info@mc3corp.com